Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

Share :
Published: 4 Jun 2012
Views: 4570
Dr George Demetri - Dana Farber Cancer Institute, Boston, USA

At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr George Demetri presented results of an international phase III trial demonstrating that the new targeted oral drug, regorafenib, can improve outcomes for patients with gastrointestinal stromal tumours (GIST) that progress due to resistance to other available treatment options, including imatinib and sunitinib.